Noninflammatory necrotizing vasculopathy in lupus nephritis: A single-center experience

Lupus

Volumn 23, Issue 1, 2014, Pages 20-30

  Chu, H ^a,b,c,d   Wu, L H ^e   Song, D ^a,b,c,d   Yu, F ^a,b,c,d   Zhao, M H ^a,b,c,d  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

^b PEKING UNIVERSITY   (China)

^c BEIJING HOSPITAL   (China)

^d BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^e NINGXIA MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; COMPLEMENT COMPONENT C3; CREATININE; CYCLOPHOSPHAMIDE; HEMOGLOBIN; LEFLUNOMIDE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ADULT; ARTICLE; CHRONICITY; CLINICAL FEATURE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; LABORATORY TEST; LEUKOCYTURIA; LEUKOPENIA; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; NONINFLAMMATORY NECROTIZING VASCULOPATHY; OUTCOME ASSESSMENT; PLASMAPHERESIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RISK FACTOR; VASCULAR DISEASE; VASCULAR NECROSIS;

ADULT; BIOPSY; COMPLEMENT SYSTEM PROTEINS; FEMALE; HUMANS; KIDNEY; LUPUS NEPHRITIS; MALE; NECROSIS; RECURRENCE; RENAL CIRCULATION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84890497484     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203313512391     Document Type: Article

References (31)

1. Weening JJ, D'Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int. 2004 ; 65: 521-530
2. Bhathena DB, Sobel BJ, Migdal SD. Noninflammatory renal microangiopathy of systemic lupus erythematosus ('lupus vasculitis'). Am J Nephrol. 1981 ; 1: 144-159
3. Appel GB, Pirani CL, D'Agati V. Renal vascular complications of systemic lupus erythematosus. J Am Soc Nephrol. 1994 ; 4: 1499-1515
4. Banfi G, Bertani T, Boeri V, et al. Renal vascular lesions as a marker of poor prognosis in patients with lupus nephritis. Gruppo Italiano per lo Studio della Nefrite Lupica (GISNEL). Am J Kidney Dis. 1991 ; 18: 240-248
5. Grishman E, Venkataseshan VS. Vascular lesions in lupus nephritis. Mod Pathol. 1988 ; 1: 235-241
6. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997 ; 40: 1725-1725
7. Liang MH, Socher SA, Larson MG, Schur PH. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum. 1989 ; 32: 1107-1118
8. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992 ; 35: 630-640
9. Wang J, Hu W, Xie H, et al. Induction therapies for class IV lupus nephritis with non-inflammatory necrotizing vasculopathy: Mycophenolate mofetil or intravenous cyclophosphamide. Lupus. 2007 ; 16: 707-712
10. Ginzler EM, Dooley MA, Aranow C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med. 2005 ; 353: 2219-2228
11. Chan TM, Tse KC, Tang CS, Lai KN, Li FK. Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine. Lupus. 2005 ; 14: 265-272
12. Wang HY, Cui TG, Hou FF, et al. Induction treatment of proliferative lupus nephritis with leflunomide combined with prednisone: A prospective multi-centre observational study. Lupus. 2008 ; 17: 638-644
13. Yu F, Tan Y, Liu G, Wang SX, Zou WZ, Zhao MH. Clinicopathological characteristics and outcomes of patients with crescentic lupus nephritis. Kidney Int. 2009 ; 76: 307-317
14. Nascimento EJ, Silva AM, Cordeiro MT, et al. Alternative complement pathway deregulation is correlated with dengue severity. PLoS One. 2009 ; 4: e6782 - e6782
15. Förster-Waldl E, Cokoja L, Förster O, Maurer W. Mannoseâ€binding lectin: Comparison of two assays for the quantification of MBL in the serum of pediatric patients. J Immunol Methods. 2003 ; 276: 143-146
16. Zadura AF, Theander E, Blom AM, Trouw LA. Complement inhibitor C4b-binding protein in primary Sjögren's syndrome and its association with other disease markers. Scand J Immunol. 2009 ; 69: 374-380
17. Song D, Wu LH, Wang FM, et al. The spectrum of renal thrombotic microangiopathy in lupus nephritis. Arthritis Res Ther. 2013 ; 15: R12 - R12
18. Austin HA 3rd, Muenz LR, Joyce KM, Antonovych TT, Balow JE. Diffuse proliferative lupus nephritis: Identification of specific pathologic features affecting renal outcome. Kidney Int. 1984 ; 25: 689-695
19. Austin HA 3rd, Boumpas DT, Vaughan EM, Balow JE. Predicting renal outcomes in severe lupus nephritis: Contributions of clinical and histologic data. Kidney Int. 1994 ; 45: 544-550
20. Cervera R, Font J, Shoenfeld Y. European Working Party on Systemic Lupus Erythematosus: A 15-year report. Autoimmun Rev. 2006 ; 5: 549-553
21. Cervera R, Abarca-Costalago M, Abramovicz D, et al. Systemic lupus erythematosus in Europe at the change of the millennium: Lessons from the "Euro-Lupus Project". Autoimmun Rev. 2006 ; 5: 180-186
22. Baldwin DS, Gluck MC, Lowenstein J, Gallo GR. Lupus nephritis. Clinical course as related to morphologic forms and their transitions. Am J Med. 1977 ; 62: 12-30
23. Tsumagari T, Fukumoto S, Kinjo M, Tanaka K. Incidence and significance of intrarenal vasculopathies in patients with systemic lupus erythematosus. Hum Pathol. 1985 ; 16: 43-49
24. Wu LH, Yu F, Tan Y, et al. Inclusion of renal vascular lesions in the 2003 ISN/RPS system for classifying lupus nephritis improves renal outcome predictions. Kidney Int. 2013 ; 83: 715-723
25. Manderson AP, Botto M, Walport MJ. The role of complement in the development of systemic lupus erythematosus. Annu Rev Immunol. 2004 ; 22: 431-456
26. Flierman R, Daha MR. Pathogenic role of anti-C1q autoantibodies in the development of lupus nephritis - a hypothesis. Mol Immunol. 2007 ; 44: 133-138
27. Yang XW, Tan Y, Yu F, Zhao MH. Combination of anti-C1q and anti-dsDNA antibodies is associated with higher renal disease activity and predicts renal prognosis of patients with lupus nephritis. Nephrol Dial Transplant. 2012 ; 27: 3552-3559
28. Lewis MJ, Malik TH, Fossati-Jimack L, et al. Distinct roles for complement in glomerulonephritis and atherosclerosis revealed in mice with a combination of lupus and hyperlipidemia. Arthritis Rheum. 2012 ; 64: 2707-2718
29. Szekanecz Z, Koch AE. Vascular involvement in rheumatic diseases: 'Vascular rheumatology'. Arthritis Res Ther. 2008 ; 10: 224-224
30. Houssiau FA, Vasconcelos C, D'Cruz D, et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis. 2010 ; 69: 61-64
31. Appel GB, Contreras G, Dooley MA, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009 ; 20: 1103-1112